LASTING SKIN HEALING

NEMLUVIO heals nodules to clear the skin1

31-year-old female actual patient at baseline with prurigo nodularis nodules on back and arms. 31-year-old female actual patient at baseline with prurigo nodularis nodules on back and arms
31-year-old female actual patient at Week 16 with healed prurigo nodularis nodules on back and arms. 31-year-old female actual patient at Week 16 with healed prurigo nodularis nodules on back and arms.
 

Baseline

Week 16

31-YEAR-OLD FEMALE.
Actual patient.

Photo altered to remove identifying marks.

REVIEW STUDY DESIGN 

>75%

of nodules healed in more than half of patients taking NEMLUVIO vs 17% with placebo (P<0.0001)1*

Data above from OLYMPIA 2. In OLYMPIA 1, 41% of patients taking NEMLUVIO achieved >75% nodule healing* vs 12% with placebo.1,2

8 out of 10 patients saw >75% of nodules healed with over a year of treatment3

Line graph showing continued skin healing over 68 weeks with NEMLUVIO®.
Line graph showing continued skin healing over 68 weeks with NEMLUVIO®.

Data from observed cases in OLYMPIA 2 treat-through population, interim analysis of the OLYMPIA LTE. No imputations for missing data. In the full population, 79% of patients (n=313) achieved PAS item 5b improvement at Week 52.3,4

REVIEW STUDY DESIGN 
Bed Icon

Sleep Improvement1

Patients saw meaningful improvements in their sleep while taking NEMLUVIO1

VIEW THE DATA 
Calendar

Q4W Dosing From the Start5

NEMLUVIO offers the convenience of less frequent dosing compared to the other biologic for PN5,6

LEARN MORE 

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are headache, dermatitis atopic, eczema, and eczema nummular.

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Please see full Prescribing Information, including Patient Information.